Francis Willard Sarena
CIK 1423786 · Chief Operating Officer · last filed 2025-10-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$172.8K
Companies
6
Total Filings
49
Lifetime Open-Market Net
-$3.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| 89bio, Inc. (ETNB) Delisted | Chief Operating Officer | 0 | $14.84 | $0 | $0 | 4 | 2025-10-30 |
| Apexigen, Inc. (APGNW) Delisted | President and COO | 155,419 | $0.03 | $4.1K | $0 | 4 | 2023-06-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Chief Strategy Officer | 122,337 | $38.00 | $4.65M | -$1.46M | 14 | 2021-04-19 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Chief Strategy Officer | 82,248 | $178.75 | $14.70M | -$2.37M | 17 | 2019-09-04 |
| FACT | VP Gen Counsel & Secy | 16,227 | $10.65 | $172.8K | $0 | 6 | 2010-04-21 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | VP/Gen Counsel/Secy | 5,756 | — | — | $0 | 2 | 2008-09-17 |
Recent Filings · Page 3 of 5
49 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-10-02 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Mixed | +969 | -$13.3K | EDGAR |
| 2018-09-05 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −2,810 | -$39.3K | EDGAR |
| 2018-02-28 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Grant (A) | +7,000 | $0 | EDGAR |
| 2017-09-07 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −3,131 | -$107.5K | EDGAR |
| 2017-03-03 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −19,784 | -$885.7K | EDGAR |
| 2017-02-09 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Grant (A) | +16,078 | $0 | EDGAR |
| 2017-01-18 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Mixed | — | -$152.2K | EDGAR |
| 2017-01-05 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Tax (F) | −2,442 | -$118.7K | EDGAR |
| 2016-11-30 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Mixed | — | -$93.4K | EDGAR |
| 2016-11-28 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Mixed | — | -$1.87M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.